PLANTATION, Fla., Oct. 14 /PRNewswire-FirstCall/ -- Viragen (Amex: VRA)
and its majority-owned subsidiary, Viragen International, Inc.
(OTC Bulletin Board: VGNI), today announced that its marketing program in
Mexico had resulted in increased demand for Multiferon(R), natural human alpha
interferon, and that additional local studies were planned to further
strengthen clinical data that supports its use for the treatment of certain
viral and malignant diseases. Viragen received a new order for Multiferon(R)
this week, the largest yet placed by Laboratorios Pisa, who holds exclusive
distribution rights to the drug in Mexico.
"The best means of improving the business of Viragen in the immediate-term
is to improve the sales of Multiferon(R), and this order indicates that our
strategic partner is gaining traction in this important market," stated
Viragen's President and CEO, Mr. Charles A. Rice. "Additionally, with new
studies planned, we expect to expose influential and leading physicians who
treat these indications in Mexico to the merits of our product, thus driving
additional revenue and business opportunities." Viragen expects to conduct
two Phase IV clinical studies in Mexico, one for the treatment of hepatitis C
and one for the treatment of chronic myelogenous leukemia (CML).
A spokesperson from Laboratorios Pisa, Mr. Javier Camacho, Director of
Marketing, confirmed the drug's expansion in Mexico: "We are pleased that we
are beginning to realize the sales and marketing efforts for Multiferon(R) and
new patients are being added each week. As our efforts in additional Mexican
territories progress, we anticipate exceeding our initial sales forecasts."
About Viragen, Inc.:
Viragen is a biotechnology company specializing in the research,
development and commercialization of natural and recombinant protein-based
drugs designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies and a peptide drug. Viragen's strategy also includes the
development of Avian Transgenic Technology as a biomanufacturing platform for
the large-scale, cost-effective production of therapeutic proteins.
Viragen is publicly traded on the American Stock Exchange (VRA).
Viragen's majority owned subsidiary, Viragen International, Inc., is publicly
traded on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners
and licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer
Center, Cancer Research UK, University of Nottingham (U.K.), University of
Miami, America's Blood Centers and the German Red Cross.
For more information, please visit: http://www.Viragen.com
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of CommunicationsPhone: (954) 233-8746;
Fax: (954) 233-1414 E-mail: dcalder@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect," "potential,"
"suggests," "may," "should," "could" or similar expressions. Such forward-
looking statements involve known and unknown risks, uncertainties and other
factors that may cause the actual results to be materially different from any
future results, performance or achievements expressed or implied by such
statements. In particular, management's expectations regarding future
research, development and/or commercial results could be affected by, among
other things, uncertainties relating to clinical trials and product
development; availability of future financing; unexpected regulatory delays or
government regulation generally; the Company's ability to obtain or maintain
patent and other proprietary intellectual property protection; and competition
in general. Forward-looking statements speak only as to the date they are
made. The Company does not undertake to update forward-looking statements to
reflect circumstances or events that occur after the date the forward-looking
statements are made.
SOURCE Viragen, Inc.
 back to top
Related links:
http://www.viragen.com
Photo Notes:http://www.newscom.com/cgi-bin/prnh/20010426/HSTH018LOGO-b
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Douglas Calder, Director of Communications,
Viragen, Inc., +1-954-233-8746, or fax, +1-954-233-1414, or
dcalder@viragen.com
|
